The U.S. Food and Drug Administration approved enzalutamide for the treatment of patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). At the prespecified interim analysis, a statistically significant improvement in overall survival was demonstrated for patients
I have been using enzalutamide in my patients who have metastatic disease proven by imaging or pathology and have progressed where hormonal therapy isn’t enough to keep the PSA near 0.